Search results
Results From The WOW.Com Content Network
Total equity. US$699.14 million (2019) Number of employees. 570 (June 30, 2020) Website. acadia .com. Footnotes / references. [1] Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Sorrento Valley, San Diego, California.
ACADIA Pharmaceuticals Reports Financial Results for the ... including $230,000 in stock-based compensation, from $4.4 million for the comparable quarter of 2011, including $128,000 in stock-based ...
ACADIA Pharmaceuticals was on fire yesterday, up 24% after presenting data for its antipsychotic pimavanserin at the American Academy of Neurology annual meeting. The data looked good.
Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Shares of ACADIA Pharmaceuticals shot through the roof today, up 30% as of this filming. In the video below, Fool health-care analyst David Williamson discusses news of some great phase 3 trial ...
Pimavanserin. Pimavanserin, sold under the brand name Nuplazid, is an atypical antipsychotic which is approved for the treatment of Parkinson's disease psychosis and is also being studied for the treatment of Alzheimer's disease psychosis, schizophrenia, agitation, and major depressive disorder. [3] Unlike other antipsychotics, pimavanserin is ...
Acadia has an antipsychotic drug sold under the brand name Nuplazid approved for patients with a type of Parkinson's disease. The company's shares clawed back some lost ground and were last down 2.1%.
Acadia (ACAD) delivered earnings and revenue surprises of 20.75% and -5.63%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?